Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45

Andrew R. Findlay, Nicolas Wein, Yuuki Kaminoh, Laura E. Taylor, Diane M. Dunn, Jerry R. Mendell, Wendy M. King, Alan Pestronk, Julaine M. Florence, Katherine D. Mathews, Richard S. Finkel, Kathryn J. Swoboda, Michael T. Howard, John W. Day, Craig M McDonald, Aurélie Nicolas, Elisabeth Le Rumeur, Robert B. Weiss, Kevin M. Flanigan

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Objective Exon-skipping therapies aim to convert Duchenne muscular dystrophy (DMD) into less severe Becker muscular dystrophy (BMD) by altering pre-mRNA splicing to restore an open reading frame, allowing translation of an internally deleted and partially functional dystrophin protein. The most common single exon deletion - exon 45 (Δ45) - may theoretically be treated by skipping of either flanking exon (44 or 46). We sought to predict the impact of these by assessing the clinical severity in dystrophinopathy patients. Methods Phenotypic data including clinical diagnosis, age at wheelchair use, age at loss of ambulation, and presence of cardiomyopathy were analyzed from 41 dystrophinopathy patients containing equivalent in-frame deletions. Results As expected, deletions of either exons 45 to 47 (Δ45-47) or exons 45 to 48 (Δ45-48) result in BMD in 97% (36 of 37) of subjects. Unexpectedly, deletion of exons 45 to 46 (Δ45-46) is associated with the more severe DMD phenotype in 4 of 4 subjects despite an in-frame transcript. Notably, no patients with a deletion of exons 44 to 45 (Δ44-45) were found within the United Dystrophinopathy Project database, and this mutation has only been reported twice before, which suggests an ascertainment bias attributable to a very mild phenotype. Interpretation The observation that Δ45-46 patients have typical DMD suggests that the conformation of the resultant protein may result in protein instability or altered binding of critical partners. We conclude that in DMD patients with Δ45, skipping of exon 44 and multiexon skipping of exons 46 and 47 (or exons 46-48) are better potential therapies than skipping of exon 46 alone. Ann Neurol 2015 Ann Neurol 2015;77:668-674

Original languageEnglish (US)
Pages (from-to)668-674
Number of pages7
JournalAnnals of Neurology
Issue number4
StatePublished - Apr 1 2015

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45'. Together they form a unique fingerprint.

Cite this